Lifecome Biochemistry: Announcement of the resolution of the third meeting of the fifth board of supervisors.
Lifecome Biochemistry: Public opinion management system.
Lifecome Biochemistry: Announcement regarding the exemption of the preparation of the previous fundraising utilization report.
Lifecome Biochemistry: Analysis report of the stock issuance plan for Lifecome Biochemistry Co., Ltd. in 2024 via simplified procedure to specific investors.
Lifecome Biochemistry: Announcement regarding issuing stocks to specific recipients through simplified procedure without providing financial assistance or compensation directly to investors participating in subscription either directly or indirectly through interested parties.
Lifecome Biochemistry: Announcement on the risk warning, filling-return measures and relevant party commitments of diluting immediate returns through the issuance of stocks to specific targets by the company using simplified procedures.
Lifecome Biochemistry: Shareholder return plan for the next three years (2024-2026).
Lifecome Biochemistry: The written review opinion of the supervisor regarding the company's issuance of stocks to specific objects in 2024 through a simplified procedure.
Lifecome Biochemistry: Announcement regarding no regulatory measures or penalties taken by securities regulatory authorities and exchanges in the past five years.
Lifecome Biochemistry: Feasibility analysis report on the use of funds raised by the issuance of stocks to specific targets through simplified procedures by Lifecome Biochemistry Co., Ltd. in 2024.
Lifecome Biochemistry: Announcement of prompt disclosure of the plan to issue stocks to specific objects through simplified procedures for the year 2024.
Lifecome Biochemistry: Lifecome Biochemistry Co., Ltd. plans to issue stocks to specific targets through a simplified procedure in 2024.
Lifecome Biochemistry: Announcement of Resolutions of the Third (Extraordinary) Meeting of the Fifth Board of Directors
Lifecome Biochemistry: Announcement on the Progress of Providing Guarantees to Wholly-owned Subsidiaries.
Lifecome Biochemistry: Announcement of Revised Performance Forecast for the First Half of 2024
Lifecome Biochemistry: Announcement of pre-disclosure of shareholding by shareholders holding more than 5% of shares who plan to reduce their holdings.
Lifecome Biochemistry: 2024 Interim Performance Forecast
Lifecome Biochemistry: Announcement of the resolution of the second meeting of the fifth board of supervisors.
Lifecome Biochemistry: Announcement regarding the transfer of equity of wholly-owned subsidiary and related transaction.
Lifecome Biochemistry: Announcement regarding the supply agreement signed between our company and the Belgian company, Shuo Teng.
No Data